Using prophylactic, but not tocolytic, magnesium sulfate to reduce cerebral palsy related to prematurity: What dose, and what about infant mortality?

Journal of Perinatal Medicine

Volumn 39, Issue 4, 2011, Pages 375-378

  Pryde, Peter G ^a   Mittendorf, Robert ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Best dose of magnesium; magnesium sulfate neuroprophylaxis; prevention of cerebral palsy; prevention of infant mortality

Indexed keywords

MAGNESIUM SULFATE; SODIUM CHLORIDE; UTERUS SPASMOLYTIC AGENT;

CEREBRAL PALSY; CLINICAL PROTOCOL; CLINICAL RESEARCH; COHORT ANALYSIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; HYPOTHESIS; INFANT; INFANT MORTALITY; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS; NEUROPROTECTION; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PREECLAMPSIA; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SEIZURE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TOCOLYSIS; TREATMENT OUTCOME;

CEREBRAL PALSY; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MAGNESIUM SULFATE; MALE; META-ANALYSIS AS TOPIC; MODELS, BIOLOGICAL; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOCOLYSIS; TOCOLYTIC AGENTS;

EID: 79960211981     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/JPM.2011.036     Document Type: Review

References (24)

1. Bennett P, Edwards D. Use of magnesium sulphate in obstetrics. Lancet. 1997;350:1491. (Pubitemid 28036548)
2. Cahill AG, Caughey AB. Magnesium for neuroprophylaxis: fact or fiction? Am J Obstet Gynecol. 2009;200:590-4.
3. Chalmers I. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann NY Acad Sci. 1993;703:156-63.
4. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev. 2002;CD001060.
5. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. J Am Med Assoc. 2003;290:2669-76. (Pubitemid 37475594)
6. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2009, Issue 1. Article. No.: CD004661. DOI: 10.1002/14651858. CD004661.pub3.
7. Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol. 2006;108:986-9. (Pubitemid 44498262)
8. Magpie Trial Collaborative Group. Do women with preeclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359:1877-90.
9. Marret S, Marpeau L, Bénichou J. Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics. 2008;121:225-6.
10. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque C, Hellot MF, et al., PREMAG trial group. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. Br J Obstet Gynaecol. 2007;114:310-8.
11. Mercer BM, Merlino AA, for the Society for Maternal-Fetal Medicine. Magnesium sulfate for preterm labor and preterm birth. Obstet Gynecol. 2009;114:650-68.
12. Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet. 1997;350: 1517-8. (Pubitemid 28036557)
13. Mittendorf R, Kuban K, Pryde PG, Gianopoulos J, Yousefzadeh D. Antenatal risk factors associated with the development of lenticulostriate vasculopathy (LSV) in neonates. J Perinatol. 2005;25:101-7. (Pubitemid 40277381)
14. Mittendorf R, Lee K-S, Roizen NJ, Pryde PG. Magnesium sulfate for preterm neuroprotection. (Letter to the Editor.) J Am Med Assoc. 2004;291:940-1. (Pubitemid 38543748)
15. Mittendorf R, Pryde PG. An overview of the possible relationship between antenatal pharmacologic magnesium and cerebral palsy. J Perinat Med. 2000;28:286-93.
16. Mittendorf R, Pryde PG, Elin R, Gianopoulos JG, Lee K-S. Relationship between hypermagnesaemia in preterm labour and adverse health outcomes in babies. Magnes Res. 2002; 15:253-61.
17. Mittendorf R, Pryde PG, Roizen N. Second overview of relationships between antenatal pharmacologic magnesium sulfate and neurologic outcomes in children. J Perinat Med. 2004;32:201-10. (Pubitemid 38737523)
18. Mittendorf R, Roizen NJ, Pryde PG. The risks of extending the controversial use of tocolytic magnesium sulfate for the purpose of neuroprotection in preterm labor. (Letter to the Editor.) J Perinatol. 2004;24:465-6. (Pubitemid 39069603)
19. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birth-weight infants? Pediatrics. 1995;95:263-9.
20. Pryde PG, Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet Gynecol. 2009;114:669-73.
21. Rouse DJ. Magnesium sulfate for the prevention of cerebral palsy. Am J Obstet Gynecol. 2009;200:610-2.
22. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008;359:895-905.
23. The American College of Obstetricians and Gynecologists: Committee (on Obstetric Practice) Opinion. Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol. 2010;115:669-71.
24. The Antenatal Magnesium Sulphate for Neuroprotection Guideline Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant, and child: National clinical practice guidelines. Adelaide: The University of Adelaide, 2010.